Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Myasthenia Gravis Treatment Global Market Report 2025
Download Free Sample Buy Now
Global Myasthenia Gravis Treatment Market Report 2025

Report Price : $4490.00

Pages :

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF
Purchase This Report

Myasthenia Gravis Treatment Global Market Report 2025

By Treatment (Medication, Surgery, Other Treatments), By Medication Type (Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, Other Medication Types), By End-Use (Hospitals, Clinics, Other End-Uses) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Myasthenia Gravis Treatment Market Overview

• Myasthenia Gravis Treatment market size has reached to $1.55 billion in 2024

• Expected to grow to $2.25 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%

• Growth Driver: Myasthenia Gravis Treatment Market Surges In Response To Escalating Disease Prevalence

• Market Trend: Product Innovations Drive Growth In Myasthenia Gravis Treatment Market With FDA Approval Of Zilucoplan

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Myasthenia Gravis Treatment Market?

Myasthenia gravis treatment refers to the process of providing health care services by health care providers and taking care of a patient to combat myasthenia gravis, an autoimmune neuromuscular disease causing fatigue and weakness in the skeletal muscles.

The main treatments for myasthenia gravis are medication, surgery, and others. Medication refers to medicine or drugs that are used to improve a particular illness, such as myasthenia gravis. Pyridostigmine is a commonly used medication for myasthenia that helps electrical signals travel between the nerves and muscles. The myasthenia gravis treatment uses various medication types such as cholinesterase inhibitors, corticosteroids, immunosuppressants, and others and is used by hospitals, clinics, and others.

Myasthenia Gravis Treatment Market Size and growth rate 2025 to 2029: Graph

What Is The Myasthenia Gravis Treatment Market Size 2025 And Growth Rate?

The myasthenia gravis treatment market size has grown strongly in recent years. It will grow from $1.55 billion in 2024 to $1.66 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to cholinesterase inhibitors, thymectomy procedures, immunosuppressive therapies, the emergence of plasma exchange, and patient advocacy

What Is The Myasthenia Gravis Treatment Market Growth Forecast?

The myasthenia gravis treatment market size is expected to see strong growth in the next few years. It will grow to $2.25 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to biologics and monoclonal antibodies, genetic and precision medicine, emerging immune modulators, neuroprotective strategies, and biosimilar medications. Major trends in the forecast period include digital therapeutics, collaborative research initiatives, patient-centric approaches, real-world evidence utilization, and long-term safety monitoring.

The forecast of 7.9% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of intravenous immunoglobulin (IVIG) and acetylcholinesterase inhibitors sourced from Austria and Ireland, thereby exacerbating autoimmune symptom flare-ups and elevating neurology treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Myasthenia Gravis Treatment Market Segmented?

1) By Treatment: Medication, Surgery, Other Treatments

2) By Medication Type: Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, Other Medication Types

3) By End-Use: Hospitals, Clinics, Other End-Uses

Subsegments:

1) By Medication: Anticholinesterase Agents, Immunosuppressants, Monoclonal Antibodies, Corticosteroids

2) By Surgery: Thymectomy

3) By Other Treatments: Plasmapheresis, Intravenous Immunoglobulin (IVIg), Supportive Therapies

What Is Driving The Myasthenia Gravis Treatment Market? Myasthenia Gravis Treatment Market Surges In Response To Escalating Disease Prevalence

The surge in the prevalence of myasthenia gravis is expected to propel the growth of the myasthenia gravis treatment market going forward. Myasthenia gravis refers to an autoimmune neuromuscular disease condition in which patients experience fatigue and weakness in the skeletal muscles. Myasthenia gravis treatment is the process of providing health care services and taking care of a patient to combat myasthenia gravis. Thus, the surge in the prevalence of myasthenia gravis is boosting sales in the myasthenia gravis treatment market. For instance, in January 2022, according to the data published by the National Organization for Rare Disorders, a US-based non-profit organization providing support for individuals with rare diseases, autoimmune myasthenia gravis had an estimated prevalence of 14–40 per 100,000 individuals in the United States. For instance, in April 2024, according to the report published by the American Journal of Managed Care, a US-based peer-reviewed journal, based on an average of 1,800 diagnoses of myasthenia gravis (MG) annually, researchers estimated an annual incidence rate of 4.32 cases per 100,000 individuals and a rate of 2.46 cases per 100,000 person-years. Therefore, the surge in the prevalence of myasthenia gravis is driving the growth of the myasthenia gravis treatment industry.

What Is Driving The Myasthenia Gravis Treatment Market? Healthcare Spending Boosts Growth In The Myasthenia Gravis Treatment Market

The increase in healthcare spending is driving the growth of the myasthenia gravis treatment market. Healthcare spending refers to the total amount of financial resources allocated to the healthcare sector within a specific region, country, or organization. Healthcare spending is used in myasthenia gravis (MG) treatment to address the autoimmune neuromuscular disorder, ensuring optimal patient care, symptom management, and improved quality of life. For instance, in July 2024, according to the American Medical Association, a US-based professional association and lobbying group of physicians and medical students, health spending in the United States increased by 4.1% in 2022 to $4.5 trillion, or $13,493 per capita. Therefore, an increase in healthcare spending is driving the growth of the myasthenia gravis treatment industry going forward.

Who Are The Major Players In The Global Myasthenia Gravis Treatment Market?

Major companies operating in the myasthenia gravis treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, Astellas Pharma Inc., CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics plc, Amneal Pharmaceuticals Inc., Kedrion SpA, CuraVac Inc., AryoGen Pharmed, RemeGen Co. Ltd., Kashiv BioSciences LLC, Immunovant Inc., Cabaletta Bio Inc., Argenx SE, NMD Pharma A/S, Cartesian Therapeutics Inc., DAS Therapeutics Inc., Harbour BioMed Holdings Ltd., AnTolRx Inc., CytoDyn Inc., Ahead Therapeutics

What Are The Key Trends Of The Global Myasthenia Gravis Treatment Market? Product Innovations Drive Growth In Myasthenia Gravis Treatment Market With FDA Approval Of Zilucoplan

Product innovations are a key trend gaining popularity in the myasthenia gravis treatment market. Major companies operating in the myasthenia gravis treatment market are focused on developing new solutions to sustain their position in the market. For instance, in October 2023, UCB Pharma, a Belgium-based pharmaceutical company, announced the US Food and Drug Administration (FDA) approved Zilucoplan. It is used for treating adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine receptor (AChR) antibodies. This approval introduces a new option in the management of gMG, which is characterized by muscle weakness due to an autoimmune response. ZILBRYSQ is notable for being a self-administered, once-daily subcutaneous complement C5 inhibitor. This provides a convenient alternative to traditional intravenous therapies that have been the standard for treating gMG.

What Are The Key Trends Of The Global Myasthenia Gravis Treatment Market? Strategic Partnership For Patient-Centered Myasthenia Gravis Treatment

Major companies operating in the myasthenia gravis treatment market are adopting a strategic partnership approach to offer a patient-centered approach to transform the way care is delivered to rare disease populations. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success. For instance, in April 2023, Huma Therapeutics, a UK-based digital health company, partnered with UCB S.A., a Belgium-based biopharmaceutical company. With this partnership, they aim to provide a digital health solution to improve the management of the rare disease Myasthenia gravis (MG).

Need data on a specific region in this market?
Request Regional Data

Myasthenia Gravis Treatment Market Merger And Acquisition: Selecta Biosciences Acquires Cartesian Therapeutics To Expand RNA-Engineered CAR-T Therapies

In November 2023, Selecta Biosciences, Inc. a US-based biotechnology company merger with Cartesian Therapeutics for an undisclosed amount. The merger strengthens Selecta's commitment to RNA cell therapies for autoimmune diseases, specifically myasthenia gravis (MG). It seeks to utilize Cartesian's cutting-edge RNA-engineering platform and pipeline, which features the promising rCAR-T therapy Descartes-08, to expedite development and deliver effective treatment solutions. Cartesian Therapeutics is a US-based biotechnology company that develops potential treatments for generalized myasthenia gravis.

Regional Outlook For The Global Myasthenia Gravis Treatment Market

North America was the largest region in the myasthenia gravis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Myasthenia Gravis Treatment Market?

The myasthenia gravis treatment market consists of sales of pyridostigmine, prednisone, azathioprine, and cyclosporine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Myasthenia Gravis Treatment Industry?

The myasthenia gravis treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the myasthenia gravis treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Myasthenia Gravis Treatment Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $1.66 billion
Revenue Forecast In 2034 $2.25 billion
Growth Rate CAGR of 7.9% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Treatment: Medication, Surgery, Other Treatments
2) By Medication Type: Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, Other Medication Types
3) By End-Use: Hospitals, Clinics, Other End-Uses Subsegments: 1) By Medication: Anticholinesterase Agents, Immunosuppressants, Monoclonal Antibodies, Corticosteroids
2) By Surgery: Thymectomy
3) By Other Treatments: Plasmapheresis, Intravenous Immunoglobulin (IVIg), Supportive Therapies
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, Astellas Pharma Inc., CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics plc, Amneal Pharmaceuticals Inc., Kedrion SpA, CuraVac Inc., AryoGen Pharmed, RemeGen Co. Ltd., Kashiv BioSciences LLC, Immunovant Inc., Cabaletta Bio Inc., Argenx SE, NMD Pharma A/S, Cartesian Therapeutics Inc., DAS Therapeutics Inc., Harbour BioMed Holdings Ltd., AnTolRx Inc., CytoDyn Inc., Ahead Therapeutics
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Myasthenia Gravis Treatment Market Characteristics

3. Myasthenia Gravis Treatment Market Trends And Strategies

4. Myasthenia Gravis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Myasthenia Gravis Treatment Growth Analysis And Strategic Analysis Framework

5.1. Global Myasthenia Gravis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Myasthenia Gravis Treatment Market Growth Rate Analysis

5.4. Global Myasthenia Gravis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Myasthenia Gravis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Myasthenia Gravis Treatment Total Addressable Market (TAM)

6. Myasthenia Gravis Treatment Market Segmentation

6.1. Global Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Medication

Surgery

Other Treatments

6.2. Global Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Cholinesterase Inhibitors

Corticosteroids

Immunosuppressants

Other Medication Types

6.3. Global Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Clinics

Other End-Uses

6.4. Global Myasthenia Gravis Treatment Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Anticholinesterase Agents

Immunosuppressants

Monoclonal Antibodies

Corticosteroids

6.5. Global Myasthenia Gravis Treatment Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Thymectomy

6.6. Global Myasthenia Gravis Treatment Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Plasmapheresis

Intravenous Immunoglobulin (IVIg)

Supportive Therapies

7. Myasthenia Gravis Treatment Market Regional And Country Analysis

7.1. Global Myasthenia Gravis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Myasthenia Gravis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Myasthenia Gravis Treatment Market

8.1. Asia-Pacific Myasthenia Gravis Treatment Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Myasthenia Gravis Treatment Market

9.1. China Myasthenia Gravis Treatment Market Overview

9.2. China Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Myasthenia Gravis Treatment Market

10.1. India Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Myasthenia Gravis Treatment Market

11.1. Japan Myasthenia Gravis Treatment Market Overview

11.2. Japan Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Myasthenia Gravis Treatment Market

12.1. Australia Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Myasthenia Gravis Treatment Market

13.1. Indonesia Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Myasthenia Gravis Treatment Market

14.1. South Korea Myasthenia Gravis Treatment Market Overview

14.2. South Korea Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Myasthenia Gravis Treatment Market

15.1. Western Europe Myasthenia Gravis Treatment Market Overview

15.2. Western Europe Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Myasthenia Gravis Treatment Market

16.1. UK Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Myasthenia Gravis Treatment Market

17.1. Germany Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Myasthenia Gravis Treatment Market

18.1. France Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Myasthenia Gravis Treatment Market

19.1. Italy Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Myasthenia Gravis Treatment Market

20.1. Spain Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Myasthenia Gravis Treatment Market

21.1. Eastern Europe Myasthenia Gravis Treatment Market Overview

21.2. Eastern Europe Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Myasthenia Gravis Treatment Market

22.1. Russia Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Myasthenia Gravis Treatment Market

23.1. North America Myasthenia Gravis Treatment Market Overview

23.2. North America Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Myasthenia Gravis Treatment Market

24.1. USA Myasthenia Gravis Treatment Market Overview

24.2. USA Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Myasthenia Gravis Treatment Market

25.1. Canada Myasthenia Gravis Treatment Market Overview

25.2. Canada Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Myasthenia Gravis Treatment Market

26.1. South America Myasthenia Gravis Treatment Market Overview

26.2. South America Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Myasthenia Gravis Treatment Market

27.1. Brazil Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Myasthenia Gravis Treatment Market

28.1. Middle East Myasthenia Gravis Treatment Market Overview

28.2. Middle East Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Myasthenia Gravis Treatment Market

29.1. Africa Myasthenia Gravis Treatment Market Overview

29.2. Africa Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Myasthenia Gravis Treatment Market Competitive Landscape And Company Profiles

30.1. Myasthenia Gravis Treatment Market Competitive Landscape

30.2. Myasthenia Gravis Treatment Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Myasthenia Gravis Treatment Market Other Major And Innovative Companies

31.1. Takeda Pharmaceutical Company Limited

31.2. Baxter International Inc.

31.3. Biogen Idec

31.4. Astellas Pharma Inc.

31.5. CSL Limited

31.6. Chugai Pharmaceutical Co. Ltd.

31.7. Grifols S.A

31.8. UCB Inc.

31.9. Mitsubishi Tanabe Pharma Corp.

31.10. Genentech Inc.

31.11. Horizon Therapeutics plc

31.12. Amneal Pharmaceuticals Inc.

31.13. Kedrion SpA

31.14. CuraVac Inc.

31.15. AryoGen Pharmed

32. Global Myasthenia Gravis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Myasthenia Gravis Treatment Market

34. Recent Developments In The Myasthenia Gravis Treatment Market

35. Myasthenia Gravis Treatment Market High Potential Countries, Segments and Strategies

35.1 Myasthenia Gravis Treatment Market In 2029 - Countries Offering Most New Opportunities

35.2 Myasthenia Gravis Treatment Market In 2029 - Segments Offering Most New Opportunities

35.3 Myasthenia Gravis Treatment Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Myasthenia Gravis Treatment Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Myasthenia Gravis Treatment Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Myasthenia Gravis Treatment Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Myasthenia Gravis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Myasthenia Gravis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Asia-Pacific, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: China, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: India, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: Japan, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Australia, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Indonesia, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: South Korea, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Western Europe, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: UK, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Germany, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: France, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Italy, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Spain, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Eastern Europe, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Russia, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: North America, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: USA, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: Canada, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: South America, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Brazil, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Middle East, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Africa, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Pfizer Inc. Financial Performance
  • Table 78: F. Hoffmann-La Roche Ltd. Financial Performance
  • Table 79: AbbVie Inc. Financial Performance
  • Table 80: Novartis AG Financial Performance
  • Table 81: AstraZeneca plc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Myasthenia Gravis Treatment Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Myasthenia Gravis Treatment Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Myasthenia Gravis Treatment Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Myasthenia Gravis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Myasthenia Gravis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Asia-Pacific, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: China, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: India, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: Japan, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Australia, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Indonesia, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: South Korea, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Western Europe, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: UK, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Germany, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: France, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Italy, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Spain, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Eastern Europe, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Russia, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: North America, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: USA, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: Canada, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: South America, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Brazil, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Middle East, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Africa, Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Pfizer Inc. Financial Performance
  • Figure 78: F. Hoffmann-La Roche Ltd. Financial Performance
  • Figure 79: AbbVie Inc. Financial Performance
  • Figure 80: Novartis AG Financial Performance
  • Figure 81: AstraZeneca plc Financial Performance

Next-Gen Primary Immunodeficiency Disorders : Market Forecast, Transformation, and Long-Term Trajectories

Read More About Next-Gen Primary Immunodeficiency Disorders : Market Forecast, Transformation, and Long-Term Trajectories

Proteus Syndrome Growth Trajectory: Key Forecasts and Strategic Insights

Read More About Proteus Syndrome Growth Trajectory: Key Forecasts and Strategic Insights

Prothrombin Complex Concentrate Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Read More About Prothrombin Complex Concentrate Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Emerging Trends Redefining the Prothrombin Complex Concentrate Market Landscape: Advanced Radiation Therapy Systems Enhancing Precision And Patient Outcomes

Read More About Emerging Trends Redefining the Prothrombin Complex Concentrate Market Landscape: Advanced Radiation Therapy Systems Enhancing Precision And Patient Outcomes

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

Read More About A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Read More About A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Read More About Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Explore the latest trends, growth insights, and forecasts in the Key Trend Shaping The Ophthalmology Medical Service Market.

Read More About Explore the latest trends, growth insights, and forecasts in the Key Trend Shaping The Ophthalmology Medical Service Market.

Musculoskeletal Disorders Drugs Global Market Report 2022 – By Type (Drugs For Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmaci...

View Report

Musculoskeletal Disorders Drugs Global Market Report 2022 – By Type (Drugs For Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmaci...

View Report

Generic Musculoskeletal Disorders Drugs Global Market Report 2025 – By Treatment Type (Medication, Therapy, Surgery, Other Treatment Types), By Disorder Type (Osteoarthritis, Rheumatoid Arthritis, Spondylarthritis, Juven...

View Report

Mycosis Fungoides Treatment Global Market Report 2025 – By Drug Type (Topical Steroids, Mechlorethamine), By Treatment Type (Photodynamic Therapy, Radiation Therapy, Targeted Therapy, Chemotherapy), By End-user (Hospital...

View Report

Tendonitis Treatment Global Market Report 2025 – By Treatment Type (Therapeutic Treatment, Hot And Cold Therapy, Physical Therapy, Shockwave Therapy, Surgical Treatment), By Condition Type (Tennis Elbow, Golfer's Elbow, ...

View Report

Myasthenia Gravis Treatment Global Market Report 2025 – By Treatment (Medication, Surgery, Other Treatments), By Medication Type (Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, Other Medication Types), B...

View Report

Muscle Pain Treatment Global Market Report 2025 – By Pharmacological Treatment (Analgesics, Muscle Relaxants, Topical Analgesics, Other Pharmacological Treatments), By Non-Pharmacological Treatment (Physical Therapy, Mas...

View Report

Muscle Tension Dysphonia Treatment Global Market Report 2025 – By Treatment Type (Drugs, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Proton-Pump Inhibitors, Analgesics, Antacids, Voice Therapy, Behavioral Counseling),...

View Report

Frequently Asked Questions

Myasthenia gravis treatment refers to the process of providing health care services by health care providers and taking care of a patient to combat myasthenia gravis, an autoimmune neuromuscular disease causing fatigue and weakness in the skeletal muscles. For further insights on this market, request a sample here

The market major growth driver - Myasthenia Gravis Treatment Market Surges In Response To Escalating Disease Prevalence. For further insights on this market, request a sample here

The myasthenia gravis treatment market size has grown strongly in recent years. It will grow from $1.55 billion in 2024 to $1.66 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to cholinesterase inhibitors, thymectomy procedures, immunosuppressive therapies, the emergence of plasma exchange, and patient advocacy. The myasthenia gravis treatment market size is expected to see strong growth in the next few years. It will grow to " $2.25 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to biologics and monoclonal antibodies, genetic and precision medicine, emerging immune modulators, neuroprotective strategies, and biosimilar medications. Major trends in the forecast period include digital therapeutics, collaborative research initiatives, patient-centric approaches, real-world evidence utilization, and long-term safety monitoring. For further insights on this market, request a sample here

The myasthenia gravis treatmentmarket covered in this report is segmented –
1) By Treatment: Medication; Surgery; Other Treatments
2) By Medication Type: Cholinesterase Inhibitors; Corticosteroids; Immunosuppressants; Other Medication Types
3) By End-Use: Hospitals; Clinics; Other End-Uses Subsegments:
1) By Medication: Anticholinesterase Agents; Immunosuppressants; Monoclonal Antibodies; Corticosteroids
2) By Surgery: Thymectomy
3) By Other Treatments: Plasmapheresis; Intravenous Immunoglobulin (IVIg); Supportive Therapies For further insights on this market, request a sample here

North America was the largest region in the myasthenia gravis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myasthenia gravis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Major companies operating in the myasthenia gravis treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, Astellas Pharma Inc., CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics plc, Amneal Pharmaceuticals Inc., Kedrion SpA, CuraVac Inc., AryoGen Pharmed, RemeGen Co. Ltd., Kashiv BioSciences LLC, Immunovant Inc., Cabaletta Bio Inc., Argenx SE, NMD Pharma A/S, Cartesian Therapeutics Inc., DAS Therapeutics Inc., Harbour BioMed Holdings Ltd., AnTolRx Inc., CytoDyn Inc., Ahead Therapeutics . For further insights on this market, request a sample here.

Major trends in this market include Product Innovations Drive Growth In Myasthenia Gravis Treatment Market With FDA Approval Of Zilucoplan. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Myasthenia Gravis Treatment Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon